Developing and commercializing novel cell therapies for neglected diseases
Cellevolve advances innovative cell therapies from discovery to commercialization, accelerating treatments that address critical unmet medical needs. Based in San Francisco, we leverage leading biomanufacturing platforms and strategic collaborations to deliver robust, scalable solutions.
Our approach is to collaborate with global innovators to bring clinical stage therapies through late-stage development and commercialization via focused clinical development, cell therapy manufacturing and a specialized platform called Cellution.
Cellution™
Our platform Cellution™ combines technologies, partners, and our teams for a customized cell therapy model. Cellevolve has developed its clinical program for the JCPyV virus-specific T cell (VST), CE-VST01-JC, and has received initial FDA feedback.
Partnership
Cellevolve has also secured a broad-based collaboration with QIMR Berghofer and its cell therapy manufacturing facility Q-Gen Cell Therapeutics. The partnership includes manufacturing clinical supply for early-stage development, and a research agreement.
Visit Cellevolve in San Francisco.
Located in the heart of San Francisco's biotech ecosystem. Stop by to learn more about our cell therapy development work, or reach out to discuss partnerships and collaboration opportunities.